Despite clear guidelines from MOHAP, many pharmaceutical companies experience avoidable delays during drug registration. Understanding common pitfalls can significantly improve approval timelines.
Incomplete Legalization of Certificates
Free Sale Certificates and GMP documents must be:
Failure to comply leads to immediate administrative deficiency.
Stability Data Non-Compliance
The UAE falls under climatic Zone IVb (hot and humid).
Stability studies must reflect:
30°C / 75% RH long-term conditions
Updated stability reports at submission
Outdated or incomplete stability data is a frequent reason for queries.
Artwork & Labeling Inconsistencies
Mismatch between pack size and dossier
Discrepancies in storage conditions
Every label detail must align with the approved file.
Delayed Response to MOHAP Queries
Regulatory timelines are partially dependent on applicant responsiveness.
Companies without structured regulatory monitoring risk extended review periods.
Improper Variation Management
Implementing changes (manufacturer, artwork, API source) without prior approval can lead to regulatory sanctions.
Key Takeaway
Most delays are preventable. Companies that treat regulatory affairs as a strategic function, not an administrative task, achieve faster and smoother approvals.
